Impact Biomedical's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Impact Biomedical in the second quarter 2026?
IMPACT BIOMEDICAL INC. achieved a return on average equity (ROE) of 9.56 % in its second quarter 2026 a new company high.

ROE has advanced compared to -464.96% in the first quarter 2026, due to net income growth.

Within the Major Pharmaceutical Preparations industry IMPACT BIOMEDICAL INC. achieved the highest return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 3824 to 3832.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-	116.02 %	114.94 %	-	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	1	-13	-12	-44	-39
Return On Equity (TTM)	9.56 %	-464.96 %	-1494.96 %	-	-375.62 %
IBO's Total Ranking	# 3832	# 3824	#	#	#
Equity (TTM) in Millions	14	15	16	-12	-7
Seq. Equity Change	-4.75 %	-5.43 %	-	-	-
Seq. Net Income Change	-	-	-	-	-

Back to IBO Management Effectiveness >> IBO's 5 Years Annual ROE >> Compare IBO ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	# 3832

Return On Equity Statistics
High	Average	Low
9.56 %	-321.91 %	-1494.96 %
(Jun 30 2026)		(Dec 31 2025)

IBO Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2022) 2023
Total Equity in Millions	16	7	33	0	0
Y / Y Equity Change	114.94 %	-77.85 %	-	-	-
Net Income in Millions	-12	-25	-7	0	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-76.31 %	-342.27 %	-21.58 %	-	-

Back to IBO Management Effectiveness >> IBO's 5 Years Annual ROE >> Compare IBO ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
IBO's' Return on Equity at Yahoo Finance
IBO's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for IBO's Competitors
Subscribers only: Roe for Impact Biomedical's Suppliers
Subscribers only: Return On Equity for IBO's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Bioventus Inc	25.96 %
Johnson and Johnson	25.74 %
Encompass Health Corporation	25.52 %
Resmed Inc	24.21 %
Healthcare Services Group Inc	24.12 %
Electromed Inc	23.65 %
Iradimed Corporation	23.45 %
Vertex Pharmaceuticals Inc	23.31 %
Lantheus Holdings Inc	23.27 %
Msa Safety Inc	23.15 %
Prestige Consumer Healthcare Inc	21.77 %
Jazz Pharmaceuticals Plc	21.37 %
Neurocrine Biosciences Inc	21.13 %
Universal Health Services Inc	20.89 %
Puma Biotechnology Inc	20.85 %
Entera Bio Ltd	20.82 %
United Therapeutics Corporation	20.18 %
Ligand Pharmaceuticals Incorporated	20.06 %
Harmony Biosciences Holdings inc	20.06 %
Pediatrix Medical Group Inc	19.89 %
Theravance Biopharma inc	19.40 %
Krystal Biotech Inc	19.34 %
Ani Pharmaceuticals Inc	19.33 %
Brightspring Health Services Inc	18.93 %
Sbc Medical Group Holdings Incorporated	18.69 %
West Pharmaceutical Services Inc	18.51 %
Intuitive Surgical Inc	17.82 %
Standard Biotools Inc	17.64 %
Inspire Medical Systems inc	17.62 %
Medinotec Inc	17.47 %

Date modified: 2026-09-26T07:44:20+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.